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Abstract — Although mathematics finds large application in physical 
sciences, its use in the medical and biological field is less usual. Nevertheless, 
mathematical models can help in understanding many medical and biological 
phenomena and they can be a powerful tool in the designing process of many 
technological devices connected to the above mentioned phenomena. Of course, 
fundamental pre-requisite for building up a reliable mathematical model is the 
deep cooperation of different competences such as those of medical doctors, 
biologists, pharmacists and engineers. This paper deals with four different 
examples of mathematical models developed by our group and dealing with 
restenosis, enzyme action on two dimensional DNA brushes, oral delivery of 
drug in amorphous or nano-crystalline form and tumour cell behaviour.
Index Terms — Biology, Mathematical model, Medicine
———————————————————
1 INTRODUCTION
If it is well known that mathematics is largely employed in the engineering, physic 
and chemistry fields, less obvious is its utility in medicine and biology. This probably 
depends on both cultural and practical reasons. Indeed, the human necessity of 
knowledge categorising favoured, in the past, the formation of impermeable barriers 
among knowledge fields that hindered the diffusion of transversal tools such as 
mathematics. Accordingly, mathematics remained in its historical nest, i.e physical 
sciences field. In addition, the typical complexity of many medical and biological 
problems did not surely encourage crossing the above mentioned barriers [1]. 
Nowadays, fortunately, the diffusion of mathematics in the medical and biological 
sciences is well established and a huge variety of examples can be cited. For example, 
Freguglia [2] edited a book dealing with theoretical aspects of evolutionary biology, 
mathematical interpretation of Darwin’s evolutionary theory, bacteria motion 
and heartbeat. Additionally, mathematics can find application, for example, in 
cardiovascular system, neuroscience, ecology, environment, evolution, immunology, 
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infectious diseases, tumor growth and therapy [3]. The spreading of mathematics 
is witnessed by the existence of many societies, such as the European Society for 
Mathematical and Theoretical Biology [4], the Society of Mathematical Biology 
[5] and the Japan Association for Mathematical Biology [6] that actively promote 
mathematics use in the medical and biological fields. Ultimately this is nothing 
more than a modern translation of the Leonardo da Vinci idea according to which “.. 
niuna umana investigazione si può dimandare vera scienzia, s’essa non passa per le 
matematiche dimostrazioni ...” (no human research can be defined true science if it 
cannot be mathematically demonstrated) [7].
While the utility of mathematics in the medical and biological fields is obvious when 
thinking to the statistical analysis of experimental findings, the help that it can 
provide in the everyday research emerges also through the mathematical modelling 
activity. Indeed, the mathematical model, defined as a mathematical metaphor of 
some aspects of reality (drug systemic spreading after oral administration, for 
example) [8], consists of the theoretical representation (imitation or emulation) of 
something or in the visualisation of something that cannot be seen (a molecule, for 
instance). Consequently, mathematical modelling can be viewed as a cognitive activity 
of the human mind aimed to the description of how devices behave or phenomena 
and processes take place. This means that a reliable mathematical model can be 
built on condition that a clear idea of how a phenomenon develops is known. Thus, 
mathematical modelling means knowledge. Accordingly, it is evident the great 
advantage that can be gained by the use of mathematical models in the medical and 
biological field in order to support and to prove very different theories.
The aim of this paper is to show some examples of mathematical models developed 
by our groups and devoted to medical and biological problems. In particular, the 
attention will be devoted to restenosis, enzyme activity in self-assembled DNA layers, 
oral drug delivery and tumor cell behviour. 
2 RESTENOSIS
Traditionally, coronary stenosis, a common atherosclerosis complication, has been matched by means of percutaneous transluminal coronary angioplasty (PTCA), 
a procedure leading to the enlargement of the stenotic portion of the coronary by 
means of an expanding balloon. Nevertheless, the high incidence of re-stenosis 
(30-40%) following PTCA [9], obliged to consider alternative approaches. The use of 
stents, rigid scaffolds positioned in correspondence of the coronary stenotic portion, 
emerged as an interesting therapeutic strategy due to the consistently reduction of 
re-stenosis occurrence with respect to the simple PTCA treatment [10]. However, 
stents did not completely solve the re-stenosis problem. Although they can really 
prevent the coronary wall early elastic recoil and late re-modelling, two known 
events leading to re-stenosis, they induce neointima iperplasia (In Stent Restenosis 
– ISR) due to the hyper-proliferation of vascular smooth muscle cells (VSMCs) [11]. 
At this purpose, the employment of drug eluting stents releasing anti-proliferative 
drugs (DES) substantially reduced the VSMCs iper-proliferation and the consequent 
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re-stenosis rate [12]. Unfortunately, however, recent studies evidence that the re-
vascularization benefit with DES is attenuated in high-risk patients (diabetes; the 
acute coronary syndromes; smaller-diameter lesions and longer lesions; several 
stents or overlapping stents), compared to low risk patients [13]. Moreover, their 
use is connected to a higher incidence of late thrombosis (due to an incomplete 
endotelisation of the stented zone) in comparison with uncoated stents [14].
In the attempt of overcoming these problems, our group and other researchers 
proposed to use of new therapeutic agents such as, nucleic acid based drugs (NABD) 
that have been proved to hinder VSMCs hyper-proliferation by suppressing the 
expression of relevant cell cycle promoting genes [15, 16, 17]. The fragile nature and low 
cellular transfection attitude impose NABD complexation with proper delivery agents 
(DA; liposomes, polycations and fatty substances, for instance) in order to make this 
approach effective and reliable from the therapeutic point of view. In addition, NABD-
DA properties (dimensions and physic-chemical characteristics) make their release 
from traditional DES problematic and alternative solutions need to be considered. 
A possible choice is represented by the endoluminal gel paving technique (EGP) [18], 
together with the implantation of a bare metal stent. EGP consists of the catheter 
application of a biocompatible polymer solution on the endoluminal vessel surface 
followed by in situ polymerization or crosslinking. The potential advantages of the gel 
paving-stent technique are an easy and safe complex loading within the gel matrix 
and the opportunity of creating a physical barrier between the damaged coronary 
wall and the overflowing thrombogenic and inflammatory elements present in the 
blood stream [19].
In the light of this frame, the developed mathematical model accounts for 1) NABD-
DA diffusion out of the gel layer towards the coronary wall and the blood stream 
2) NABD-DA convective motion in the coronary wall portion not shielded by the gel 
layer (this convective contribute is due to the radial hydrostatic pressure gradient 
between lumen and coronary wall) and 3) NABD-DA metabolism and internalisation 
into cells. In order to reduce the intrinsically three dimensional problem to a simpler 
two dimensional problem, the stent is schematised by a series of equally spaced rings 
that cannot be crossed by NABD-DA. In addition, with the aim of accounting for really 
occurring situations, two different stent positions with respect to the coronary wall 
are considered: stent strut totally embedded or totally out of the coronary wall [20]. 
The performed simulations make clear that in order to hinder all the stages leading 
to re-stenosis (thrombi deposition 0-10 days, VSMCs proliferation 2.5 – 25 days, late 
remodelling and inflammation 25 – 300 days) it is necessary to complex the NABD 
with at least two DA differing in size. Indeed, small DA guarantees a rapid diffusion 
of the NABD-DA complex that can hinder the fast re-stenosis phenomena (thrombi 
deposition and beginning of VSMCs proliferation). Big DA ensures a slow diffusion of 
the NABD-DA complex that can hinder the long occurring re-stenosis phenomena 
(late VSMCs proliferation, late remodelling and inflammation).
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3 ENzyME
The immobilization of dense DNA structures on solid supports (ultra-flat gold surface), obtained by self-assembly and enzymatic manipulations, holds a central 
role as a tool for developing miniaturized devices with innovative applications, ranging 
from biosensing [21] to next-generation information technology [22]. For example, 
restriction enzymes, that cleave double-stranded (ds) DNA molecules, are widely 
utilized in cloning as well as in a number of DNA-based assays [23] because they 
target very specific dsDNA sites. Moreover, these enzymes have the ability to diffuse 
in one-dimension by sliding on the backbone of long dsDNA filaments during their 
site-searching process [24]. Recently, it was studied the behaviour of a restriction 
enzyme reaction (DpnII) with dsDNA oligomers packed into relatively large (and flat) 
surface-bound brushy matrices consisting of patches of monolayer with controlled 
density [25]. The enzyme action was followed by measuring the height reduction of the 
dsDNA brush because of cleavage using atomic force microscopy (AFM). It was found 
that the restriction reaction depends on the DNA density, and it was demonstrated 
the existence of a threshold above which the reaction is inhibited (essentially in a 
stepwise manner). This result, which has been later confirmed by other groups [26], 
suggested that the accessibility of dsDNA molecules in these surface-bound brushy 
matrices critically depends on the inherent steric hindrance. In particular, we saw that 
while enzyme cannot enter inside the dsDNA monolayer through the upper surface 
(i.e. that formed by dsDNA free end), the access is only allowed through the lateral 
dsDNA brush side. We explained these results by modelling the steric hindrance of 
the dsDNA brush in the upper and side surface [27]. This model was inspired by an 
established theory describing the diffusion of solutes inside polymer matrices [28]. 
Once this peculiar behaviour was elucidated, the attention was focussed on the 
mathematical description of enzyme diffusion and reaction inside the two dimensions 
dsDNA brush. In particular, the model was based on the idea that the 2D enzyme 
movement occurs according to Fick’s law while enzyme reaction kinetics took place 
according to the Michaelis-Menten scheme where the reaction constants are those 
experimentally determined in bulk. On the basis of this model, it was then possible 
simulating the enzyme action (dsDNA cutting) on the two dimensions brush.
4 ORAL DELIVERy
Many pharmaceutical systems are essentially made up of a polymeric carrier hosting the active agent (drug) inside its three-dimensional network [29]. 
Especially in the case of oral administration, they are often prepared as particulate 
systems since these forms present remarkable advantages over the single unit 
devices. The easier dispersion inside the stomach reflects into an appreciable 
reduction of the local drug concentration which is usually responsible for gastric 
irritation. Moreover, they are very versatile and powerful as drug loading into cross-
linked polymers can represent a profitable tool to increase the drug dissolution rate 
in aqueous media and, thus, the bioavailability of slightly water-soluble crystalline 
drugs [1]. Indeed, by means of different techniques such as solvent swelling, co-
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grinding or supercritical CO2 it is possible loading drug nanocrystals and amorphous 
drug inside polymeric matrices [1]. The interesting aspect of nanocrystals is that 
their solubility increases with reducing their dimension up to the amorphous state 
that can be viewed as a crystal of vanishing dimension [30]. Thus, they are more 
bioavailable than bulk (macro) crystals [31] and their use implies dose reduction, with 
clear benefits for what concerns the reduction of side effects and costs. In order to 
theoretically study the in vivo behaviour of these “activated” systems, we built up 
a mathematical model accounting for the simultaneous processes of drug release 
from the particulate systems and the drug spreading into the body. In particular, 
the release stage considered the phenomena concerning particle swelling, drug 
solubilisation and drug diffusion in the polymeric network. The spreading step, 
instead, accounted for drug absorption, partitioning among tissues and elimination/
metabolism (ADME processes) [32]. This model proved to be a reliable tool to fit both 
in vitro and in vivo experimental data. Accordingly, it is a powerful mean to properly 
design delivery systems based on polymeric particles containing drug nanocrystals 
and amorphous drug.
5 TUMOUR CELL BEhAVIOUR
We have employed mathematical models also to describe the behaviour of different forms of tumour cells including prostate cancer cells. From the medical 
point of view, we are interested in studying the behaviour of prostate tumour cells 
as this kind of tumour is the main cause of cancer death in males in the Western 
World and also in Friuli Venezia Giulia (Registro Tumori 199-2003). By mathematical 
modelling, we could properly compare the growth rate of different types of prostate 
cancer cells and make interesting correlations with the expression genes (eEF1A1 
and eEF1A2) representing potential markers for prostate cell transformation and/or 
of cancer progression [33]. Shortly we will use the mathematical approach developed 
to study the growth behaviour of prostate cancer cell upon the treatment by NABD 
(work in progress); this approach will allow us to shorten the experimental procedure 
providing a sharp picture of the effect of our molecules in different prostate cancer 
cell lines. Finally, it should be noted that a similar approach will be followed for NABD 
molecules directed against genes involved in the generation and development of 
hepatocellular carcinoma [34, 35], another relevant tumour pathology in Friuli Venezia 
Giulia. 
6 CONCLUSIONS
Mathematical modelling can be a powerful tool for the understanding of many phenomena occurring in medicine and biology and, consequently, a powerful 
tool for the designing of devices connected to these phenomena. Of course, due 
to the complexity of the phenomena occurring in medicine and biology, a reliable 
mathematical model can be obtained on condition that many different competences 
concur in its building up. Accordingly, for example, the deep cooperation of medical 
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doctors, biologists, pharmacists and engineers is requested. We believe that this is 
the winning strategy for the challenges proposed by the modern research.
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